Bespalov V G, Beliaeva O A, Kireeva G S, Senchik K Iu, Stukov A N, Aristova V A, Vyshinskaia E A, Kon'kov S A, Krylova I A, Semënov A L, Maĭdin M A, Aleksandrov V A, Beliaev A M
Vopr Onkol. 2014;60(2):72-9.
The study of antitumor efficacy of dioxadet in chemoperfusion treatment of ascitic ovarian cancer was carried out in 125 Wistar female rats. Ovarian cancer was inoculated intraperitoneally at a number 1x10(7) tumor cells per rat. Intraperitoneal administration of dioxadet as well as chemoperfusion was performed once in 48 hours after the ovarian cancer inoculation. Dioxadet was used at maximal tolerated doses which were 1.5 mg/kg for intraperitoneal administration, 30 mg/kg for normothermic intraperitoneal chemoperfusion (IPEC), and 15 mg/kg for hyperthermic intraperitoneal chemoperfusion (HIPEC). Antitumor effects of dioxadet were estimated in increase of median survival. In the control group, where animals didn't receive any treatment, the median survival was 9 days. Increase of the median survival after intraperitoneal administration of dioxadet, IPEC and HIPEC with dioxadet was 211% (p=0,001), 244% (p=0,001) and 444% (p=0,001), respectively, compared to the control group. Hence, intraperitoneal chemoperfusion with dioxadet (normo- or hyperthermic) is more effective compared to standard intraperitoneal administration of the drug. At HIPEC with dioxadet potentiating antitumor action of hyperthermia and dioxadet on the ovarian cancer growth was achieved.
在125只Wistar雌性大鼠中开展了二恶烷在腹水型卵巢癌化学灌注治疗中的抗肿瘤疗效研究。以每只大鼠接种1×10⁷个肿瘤细胞的数量腹腔内接种卵巢癌。在接种卵巢癌后48小时，每48小时进行一次二恶烷腹腔内给药以及化学灌注。二恶烷以最大耐受剂量使用，腹腔内给药为1.5mg/kg，常温腹腔内化学灌注（IPEC）为30mg/kg，热腹腔内化学灌注（HIPEC）为15mg/kg。通过中位生存期的增加来评估二恶烷的抗肿瘤效果。在未接受任何治疗的对照组中，中位生存期为9天。与对照组相比，腹腔内给予二恶烷、二恶烷IPEC和二恶烷HIPEC后中位生存期的增加分别为211%（p = 0.001）、244%（p = 0.001）和444%（p = 0.001）。因此，与该药物的标准腹腔内给药相比，二恶烷（常温或热）腹腔内化学灌注更有效。在二恶烷HIPEC中，实现了热疗和二恶烷对卵巢癌生长的增效抗肿瘤作用。
